Defymed plus Semma Therapeutics inked a collaboration focused on combining Defymed’ s bioartificial pancreas, MAILPAN® (MAcro-encapsulation of PANcreatic Islets), with Semma’ s stem cell-derived differentiated insulin-secreting tissue, for treating type 1 diabetes. The partners try to carry out preclinical validation to demonstrate effectiveness and safety from the device in vitro, and in an animal model.

MAILPAN is effectively a biocompatible, polymer pouch composed of semi-permeable membranes, and containing encapsulated pancreatic cells. The pv cells receive nutrients and oxygen, and can deliver insulin towards the body, but are isolated from immune system’ h cells and antibodies, which the firms claim negates the advantages of immunosuppressants.

“ Semma Therapeutics’ expertise can represent a major new source for cells usable within our medical device, ” said Sé verine Sigrist, Ph level. D., founding president and scientific director of Defymed. “ It is vital in Defymed’ s strategy to validate the medical device with what are currently the most promising cells. All of us believe the approach developed by Semma is the most advanced globally. ”

In July, Defymed was granted up to $500, 000 by the JDRF to progress preclinical research with MAILPAN. More recently, in October, the firm collaborated with molecular biomimetics specialist, Symbiose Biomaterials, for a task designated CODEPI, which aims to develop an antimicrobial peptide compress that can be used for skin disinfectation, and also during filling up and emptying of the MAILPAN bioartificial pancreas.

Semma Therapeutics is focused on the development of cell-based therapies pertaining to diabetes. In September, the firm received a $5 million grant from California Institute of Regenerative Medication to develop a personalized cell therapy for diabetes depending on generating stem cell-derived pancreatic islets from diabetic patients’ own cells.